Tag #Neoantigens

Showing 1 to 4 of 4 results

foxnews.com

🌐 85% Global Worthiness

Feb 13, 01:08

Personalized Cancer Vaccine Shows Promise in Treating Advanced Kidney Cancer

A new personalized cancer vaccine shows promise in treating advanced kidney cancer; in a small study, nine patients with stage 3 or 4 kidney cancer remained cancer-free for an average of 34.7 months after receiving a vaccine tailored to their specific tumor type, triggering a significant immune resp...

Personalized Cancer Vaccine Shows Promise in Treating Advanced Kidney Cancer

A new personalized cancer vaccine shows promise in treating advanced kidney cancer; in a small study, nine patients with stage 3 or 4 kidney cancer remained cancer-free for an average of 34.7 months after receiving a vaccine tailored to their specific tumor type, triggering a significant immune resp...

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the immediate, specific impacts of this new personalized kidney cancer vaccine on patient outcomes in the reported clinical trial?

A new personalized cancer vaccine shows promise in treating advanced kidney cancer. In a small study of nine patients with stage 3 or 4 kidney cancer, all remained cancer-free after an average of 34.7 months following vaccination. The vaccine, tailored to each patient's tumor, triggered a significant immune response, with T-cells increasing over 166 times within three weeks.

forbes.com

🌐 85% Global Worthiness

Feb 5, 22:13

Personalized Cancer Vaccine Shows Promising Results in Kidney Cancer Trial

A phase I trial at Dana-Farber Cancer Institute showed that a personalized cancer vaccine kept nine kidney cancer patients cancer-free for three years post-treatment; this is a significant advancement given the high recurrence rate of kidney cancer.

Personalized Cancer Vaccine Shows Promising Results in Kidney Cancer Trial

A phase I trial at Dana-Farber Cancer Institute showed that a personalized cancer vaccine kept nine kidney cancer patients cancer-free for three years post-treatment; this is a significant advancement given the high recurrence rate of kidney cancer.

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the immediate significance of the successful phase I trial of a personalized cancer vaccine for kidney cancer?

A new personalized immunotherapy, a cancer vaccine, has shown promising results in a phase I trial for kidney cancer. Nine patients at Dana-Farber Cancer Institute remained cancer-free three years post-treatment, a significant outcome given kidney cancer's high recurrence rate. This success is particularly noteworthy because the vaccine targets unique tumor characteristics, effectively 'steering' the immune system.

elpais.com

🌐 85% Global Worthiness

Feb 6, 01:10

Personalized Cancer Vaccine Shows Promise in Advanced Kidney Cancer

A small study of nine patients with advanced kidney cancer showed promising results using a personalized vaccine targeting neoantigens; after three years, all patients remained cancer-free, suggesting a new approach to treating this challenging disease.

Personalized Cancer Vaccine Shows Promise in Advanced Kidney Cancer

A small study of nine patients with advanced kidney cancer showed promising results using a personalized vaccine targeting neoantigens; after three years, all patients remained cancer-free, suggesting a new approach to treating this challenging disease.

Progress

44% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the immediate implications of a personalized cancer vaccine showing complete remission in a small study of advanced kidney cancer patients?

A personalized cancer vaccine, developed from a patient's tumor tissue, has shown promising results in a small study of nine patients with advanced kidney cancer. After surgery and in some cases, immunotherapy, all patients remained cancer-free for three years. This innovative approach targets specific mutated proteins (neoantigens) unique to cancer cells, stimulating a powerful immune response.

repubblica.it

🌐 85% Global Worthiness

Jan 15, 16:10

Shared Neoantigens in Endometrial Cancers Suggest Potential for Nous-209 Vaccine

An Italian study found that endometrial cancers with mismatch repair deficiency share many neoantigens with colon and stomach cancers, suggesting the potential use of the existing Nous-209 therapeutic vaccine; 80% of 35 patients showed at least one neoantigen present in Nous-209.

Shared Neoantigens in Endometrial Cancers Suggest Potential for Nous-209 Vaccine

An Italian study found that endometrial cancers with mismatch repair deficiency share many neoantigens with colon and stomach cancers, suggesting the potential use of the existing Nous-209 therapeutic vaccine; 80% of 35 patients showed at least one neoantigen present in Nous-209.

Progress

20% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How does the study's finding of shared neoantigens between different cancer types contribute to the development of therapeutic cancer vaccines?

This pre-clinical proof-of-concept study establishes a rationale for expanding Nous-209 trials to include endometrial cancer patients. The shared neoantigens, resulting from mismatch repair defects, indicate a potential mechanism for effective immunotherapy across multiple cancer types. Eighty percent of the endometrial cancer patients studied possessed at least one neoantigen present in Nous-209.

Showing 1 to 4 of 4 results